Trastuzumab (Herceptin), a recombinant humanized IgG monoclonal antibody, binds to the extracellular domain IV of HER2 for antitumor activity and was approved by the US Food and Drug Administration as first-line treatment of advanced HER2-positive gastric cancer (8). This evidence concerns the gene ERBB2 and gastric cancer.